Compare Stocks → Elon Musk’s Controversial New Project: “Apollo” (From InvestorPlace) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:GEMPNASDAQ:MTPOTCMKTS:NSPXNASDAQ:SNNANASDAQ:XBIO Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGEMPGemphire Therapeutics$3.12-7.4%$4.97$0.24▼$1.49$46.40M2.82127,174 shs23,389 shsMTPBiodexa Pharmaceuticals$1.95$0.29▼$5.25$6.18M2.2957,354 shs164,300 shsNSPXInspyr Therapeutics$0.00$0.00▼$0.07$1.47M-17.3313.19 million shs29.64 million shsSNNASienna Biopharmaceuticals$0.14$0.14$0.06▼$3.80$4.20M2.671.87 million shs13.32 million shsXBIOXenetic Biosciences$3.85+2.4%$4.08$2.55▼$5.97$5.79M2.67,203 shs2,719 shs7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGEMPGemphire Therapeutics-7.42%-11.61%-30.04%-1.89%+358.15%MTPBiodexa Pharmaceuticals0.00%0.00%0.00%0.00%0.00%NSPXInspyr Therapeutics0.00%0.00%0.00%0.00%0.00%SNNASienna Biopharmaceuticals0.00%0.00%0.00%0.00%0.00%XBIOXenetic Biosciences+1.85%-4.11%-0.26%+17.74%-12.02%Elon Musk’s Controversial New Project: “Apollo” (Ad)Have you seen this footage outside the headquarters of Elon Musk's "Project Apollo?" Big Tech and the mainstream media have called this project "controversial"...Click here to see the details because there's a lot of money at stake.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGEMPGemphire TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AMTPBiodexa PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ANSPXInspyr TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ASNNASienna BiopharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AXBIOXenetic BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGEMPGemphire TherapeuticsN/AN/AN/AN/AMTPBiodexa PharmaceuticalsN/AN/AN/AN/ANSPXInspyr TherapeuticsN/AN/AN/AN/ASNNASienna BiopharmaceuticalsN/AN/AN/AN/AXBIOXenetic Biosciences2.00HoldN/AN/ACurrent Analyst RatingsSales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGEMPGemphire TherapeuticsN/AN/AN/AN/A$0.54 per shareN/AMTPBiodexa Pharmaceuticals$800K0.00N/AN/A$5.67 per share0.00NSPXInspyr TherapeuticsN/AN/AN/AN/A($0.07) per shareN/ASNNASienna BiopharmaceuticalsN/AN/AN/AN/A$1.27 per shareN/AXBIOXenetic Biosciences$2.54M2.33N/AN/A$6.36 per share0.61Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGEMPGemphire Therapeutics-$23.64MN/A0.00∞N/AN/A-419.70%-173.05%N/AMTPBiodexa Pharmaceuticals-$7.51MN/A0.00N/AN/AN/AN/AN/AN/ANSPXInspyr Therapeutics-$6.30MN/A0.00N/AN/AN/AN/A-1,354.49%N/ASNNASienna Biopharmaceuticals-$73.47M-$3.59N/AN/AN/AN/A-177.36%-52.22%N/AXBIOXenetic Biosciences-$4.14M-$2.75N/AN/AN/A-162.84%-36.43%-33.74%5/9/2024 (Estimated)Latest XBIO, NSPX, SNNA, MTP, and GEMP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/21/2024Q4 2023XBIOXenetic Biosciences-$0.87-$0.77+$0.10-$0.77$0.68 million$0.67 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGEMPGemphire TherapeuticsN/AN/AN/AN/AN/AMTPBiodexa PharmaceuticalsN/AN/AN/AN/AN/ANSPXInspyr TherapeuticsN/AN/AN/AN/AN/ASNNASienna BiopharmaceuticalsN/AN/AN/AN/AN/AXBIOXenetic BiosciencesN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGEMPGemphire TherapeuticsN/A0.670.67MTPBiodexa PharmaceuticalsN/AN/AN/ANSPXInspyr TherapeuticsN/A0.090.09SNNASienna BiopharmaceuticalsN/A15.2715.27XBIOXenetic BiosciencesN/A11.8411.84OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGEMPGemphire Therapeutics17.53%MTPBiodexa Pharmaceuticals4.21%NSPXInspyr Therapeutics0.02%SNNASienna Biopharmaceuticals17.36%XBIOXenetic Biosciences15.12%Insider OwnershipCompanyInsider OwnershipGEMPGemphire Therapeutics22.70%MTPBiodexa Pharmaceuticals0.34%NSPXInspyr Therapeutics0.02%SNNASienna Biopharmaceuticals27.20%XBIOXenetic Biosciences9.00%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableGEMPGemphire Therapeutics914.87 millionN/ANot OptionableMTPBiodexa Pharmaceuticals1821.67 million21.60 millionNot OptionableNSPXInspyr Therapeutics1543.15 millionN/ANot OptionableSNNASienna Biopharmaceuticals3930.91 millionN/ANot OptionableXBIOXenetic Biosciences41.54 million1.40 millionNot OptionableXBIO, NSPX, SNNA, MTP, and GEMP HeadlinesSourceHeadlineXenetic Biosciences Inc (XBIO)investing.com - April 10 at 3:28 PMXenetic Biosciences Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lagfinance.yahoo.com - March 24 at 5:09 PMXenetic Dips on Full-Year Resultsbaystreet.ca - March 22 at 7:33 PMXenetic Biosciences reports FY resultsmsn.com - March 22 at 8:51 AMXenetic Biosciences, Inc. Reports Full Year 2023 Financial Resultsaccesswire.com - March 22 at 8:00 AMXenetic to advance DNase programme with UVA partnershipmsn.com - January 18 at 1:37 PMXenetic Biosciences Inc XBIOmorningstar.com - January 4 at 5:10 PMXenetic Biosciences Stock (NASDAQ:XBIO), Guidance and Forecastbenzinga.com - December 11 at 9:01 AMMost Shareholders Will Probably Agree With Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Compensationfinance.yahoo.com - November 30 at 10:39 AMXenetic Biosciences: Q3 Earnings Insightsbenzinga.com - November 10 at 3:38 PMMediciNova: Q3 Earnings Snapshotwashingtonpost.com - November 10 at 10:37 AMXenetic Biosciences, Inc. to Participate at the Virtual Investor Ask the CEO Conferencefinance.yahoo.com - October 11 at 9:30 AMXenetic Biosciences (XBIO) Upgraded to Strong Buy: What Does It Mean for the Stock?msn.com - July 13 at 1:44 PMXenetic Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business Updatefinance.yahoo.com - May 11 at 5:06 PMXenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. Cullison | Morningstarmorningstar.com - May 5 at 10:21 AMXenetic Biosciences, Inc. Bolsters R&D and Regulatory Expertise with Appointment of Reid P. Bissonnette, Ph.D. as Executive Consultant for Translational Research and Developmentfinance.yahoo.com - May 4 at 10:02 AMXenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. Cullisonfinance.yahoo.com - May 3 at 10:26 AMHC Wainwright & Co. Reiterates Xenetic Biosciences (XBIO) Buy Recommendationmsn.com - April 12 at 10:37 PMXenetic Biosciences forms research collaboration with TSRIpharmaceutical-technology.com - April 12 at 12:36 PMAnalysts Offer Insights on Healthcare Companies: Adaptimmune Therapeutics (ADAP) and Xenetic Biosciences (XBIO)markets.businessinsider.com - April 12 at 2:30 AMXenetic Biosciences, Inc. Announces Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platformfinance.yahoo.com - April 11 at 8:43 AMJTC Team, LLC: JTC Team to Host Virtual Investor NETs in Cancer Spotlight Event Featuring Xenetic Biosciencesfinanznachrichten.de - March 16 at 12:09 PMJTC Team to Host Virtual Investor NETs in Cancer Spotlight Event Featuring Xenetic Biosciencesfinance.yahoo.com - March 16 at 12:09 PMXBIO Xenetic Biosciences, Inc.seekingalpha.com - February 23 at 11:29 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsGemphire TherapeuticsNASDAQ:GEMPGemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia and nonalcoholic fatty liver disease (NAFLD/NASH). The company is developing gemcabene, a novel, once-daily, and oral therapy for dyslipidemia conditions where patients are unable to reach their lipid lowering goals, including patients already receiving maximally tolerated statin therapy. It also completed three Phase IIb clinical trials for gemcabene in homozygous familial hypercholesterolemia (HoFH) and hypercholesterolemia, including heterozygous familial hypercholesterolemic (HeFH) and atherosclerotic cardiovascular disease (ASCVD) patients on maximally tolerated statins, and severe hypertriglyceridemia (SHTG). The company was founded in 2008 and is headquartered in Livonia, Michigan.Biodexa PharmaceuticalsNASDAQ:MTPBiodexa Pharmaceuticals Plc is a drug delivery technology company. It is focused on the research and development of medicines for rare cancers, via both in-house programs as well as partnered programs. The firm's proprietary platform drug delivery technologies are Q-Sphera platform is a disruptive polymer microsphere technology, which is used for sustained release at the microscale to prolong and control the release of therapeutics over an extended period of time from weeks to months; Midasolve platform is an innovative nano saccharide technology, which is used to dissolve drugs at the nanoscale so that they can be administered in liquid form directly and locally into tumors; Midacore platform is an edge gold nanoparticle technology, which is used for targeting sites of disease at the nanoscale. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.Inspyr TherapeuticsOTCMKTS:NSPXInspyr Therapeutics, Inc. is a pharmaceutical company, which engages in the research and development of novel therapeutics for the treatment of cancer. Its product pipeline includes Mipsagargin, a dual A2A/A2B antagonist, an A2A antagonist, an A2B antagonist, and an A2A agonist. The company was founded by Craig A. Dionne, John T. Issacs, and Samuel R. Denmeade on November 21, 2003 and is headquartered in Westlake Village, CA.Sienna BiopharmaceuticalsNASDAQ:SNNASienna Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that focuses on the discovery, clinical development, and commercialization of aesthetics and medical dermatology. Its products include Topical by Design platform for patients with inflammatory skin diseases and other dermatologic and aesthetic conditions through SNA-120, SNA-125, and SNA-001. The company was founded by Todd Harris and Frederick C. Beddingfield III on July 27, 2010 and is headquartered in Westlake Village, CA.Xenetic BiosciencesNASDAQ:XBIOXenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.